Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting oggi, 14:10 ansa.it 0 0
Cina, addio crescita del 5%? Quanto è grave la crisi cinese secondo gli ultimi dati oggi, 13:02 money.it 0 0
Nessun commento